The Food and Drug Administration today issued draft guidance describing the premarket studies that manufacturers should conduct for blood glucose monitoring systems intended for use in professional health care settings. Based on feedback from the clinical community, the guidance recommends that manufacturers ensure the studies are designed to support a Clinical Laboratory Improvement Amendments waiver for the device. A CLIA waiver allows hospitals to use the device at the point of care. Historically, FDA has not distinguished between requirements for blood glucose monitoring systems used in hospitals and other health care settings and over-the-counter meters used for self-monitoring, which are automatically waived under CLIA. FDA will accept comments on the draft guidance for 90 days after its publication in the Federal Register. 
 

Related News Articles

Headline
The Food and Drug Administration today reported 55 injuries and one death involving an infusion pump and vital signs monitoring system. Becton Dickinson…
Headline
The Food and Drug Administration today announced a voluntary pilot program to expedite approvals of certain changes to ethylene oxide sterilization processes…
Headline
The Food and Drug Administration should study potential alternatives to ethylene oxide for sterilizing medical devices, but a solution could be at least a…
Headline
The Food and Drug Administration today recommended medical device manufacturers, health care providers and patients take certain actions to reduce the risk…
Headline
To reduce risk of patient infection, the Food and Drug Administration recommends health care facilities transition to using duodenoscopes with disposable…
Headline
Medtronic has recalled certain MiniMed insulin pumps due to cybersecurity risks, and will provide alternative pumps to the estimated 4,000 U.S. patients using…